We report the case of a patient with known history of systemic lupus erythematosus (SLE) who developed diffuse large B-cell lymphoma of the central nervous system after almost 8 years of treatment with mycophenolate mofetil (MMF). A 43year-old Chinese woman was admitted in April 2008 for gradual onset of left-sided weakness for 1 week. She was diagnosed to have SLE in 1992 when she presented with malar rash, migratory arthralgia, early morning stiffness, elevated anti-nuclear and anti-double stranded (ds) DNA antibodies. She was given low-dose prednisolone with satisfactory control of her symptoms until she presented with proteinuria of 3.8 g per day in June 2000 with biopsy proven active lupus nephritis of WHO Class IV. She was treated with prednisolone 50 mg and MMF 1 g daily. She failed to tolerate a higher dose of MMF with significant diarrhoea. She achieved a partial response with residual proteinuria in the range of 0.6 to 0.9 g per day. MMF was tailed down to 500 mg daily and concomitant azathioprine 50 mg daily was then added as a steroid sparing agent since July 2002.
The patient was alert and oriented upon admission. She was afebrile and her blood pressure was 170/103 mmHg with a regular heart rate of 90 beats per minute. Physical examination showed left upper motor neuron type facial weakness and left hemiparesis with grade 3 limb power associated with hyperreflexia and an extensor plantar response over the left side. There was no gross sensory deficit, no nystagmus or cerebellar signs. There was no rash, no palpable lymphadenopathy and no hepatosplenomegaly. Complete blood picture showed normal white blood cell count of 4.4 (normal (N) 4.4-10.1) Â 10 9 /l with a differential neutrophil count of 3.6 (N 2.2-6.7) Â 10 9 /l and lymphocyte count of 0.2 (N 1.2-3.4) Â 10 9 /l and elevated erythrocyte sedimentation rate (84 mm/h). She had normal liver and renal function and normal lactate dehydrogenase (183 (N 107-218) U/L). Serology revealed slightly elevated anti-dsDNA antibody level (63 (N 0-35) IU/ml), depressed C3 level (36 (N 76-150) mg/dl) and normal C4 level (13 (N 9-35) mg/dl) which had been stable compared with the last check 1 month ago. The patient's serum C3 level had been low since the onset of disease and she was believed to have genetic C3 deficiency. The level of C-reactive protein was below the detectable limit (<0.35 mg/dl). Blood culture showed no growth.
Standby computed tomography (CT) scan of the brain showed no obvious mass or hydrocephalus. Magnetic resonance imaging (MRI) of the brain demonstrated a focal mass 1.5 Â 1.4 Â 1.6 cm 3 in the subcortical part of the right high parietal region, located within the right precentral gyrus with perifocal oedema. The lesion was isointense to grey matter on both T1-and T2-weighted images and was associated with rim enhancement after gadolinium administration ( Figure 1A and B ). Isointensity on the T2-weighted image favoured high cellularity lesions such as lymphoma. Cerebrospinal fluid (CSF) analysis showed no pleiocytosis, normal CSF levels of protein (0.35 (N 0.12-0.60) g/l) and glucose (2.9 (N 2.2-3.9) mmol/l). Bacterial and viral cultures of the CSF showed no growth and cytology was negative for malignant cells. Serology for human immunodeficiency virus (HIV) was negative.
Craniotomy with excision of the entire supratentorial mass was performed. Intraoperative brain biopsy was not diagnostic but showed extensive necrosis with foci of increased cellularity and some cytological atypia only. Paraffin material later revealed diffuse sheets of large lymphoid cells in which many 'immunoblast-like' cells were noted (Figure 2A ). Immunohistochemistry demonstrated strong membranous expression of CD20 on the tumour cells ( Figure 2B ). The tumour was negative for cytokeratin markers MNF116, AE1/3 and S100. In-situ hybridization (ISH) studies for Epstein-Barr virus (EBV)-encoded RNA (EBER) showed a strong positive signal in the large B-cell population ( Figure 2C ). The patient was diagnosed to have EBV driven large B-cell lymphoproliferative disease. Haematologists were consulted and azathioprine and MMF were stopped. PET-CT scan and bone marrow for staging showed no evidence of lymphoma elsewhere. She was treated with highdose intravenous methotrexate 3 g every 3-4 weeks for three times and whole brain radiotherapy. Experimental use of intrathecal rituximab 25 mg was also given monthly on two occasions. There was complete remission of the lymphoma and the patient showed gradual improvement in her limb power with residual mild hemiparesis of grade 4. Her serum C3 level remained low (41 mg/dl). 
Discussion
Lymphoproliferative disorders including primary lymphoma of the central nervous system (PCNSL) are a well-recognized complication of systemic immunosuppression following organ transplantation and HIV infection. 1 PCNSL is not common and accounts for only 2-3% of non-Hodgkin lymphoma (NHL) cases. The first case of lupus-associated PCNSL related to MMF use involved a Korean patient with active lupus nephritis treated with MMF 2 g daily for 1 year. 2 Another case of PCNSL occurred in an African-American lupus patient treated with MMF 1 g daily for lupus nephritis for 6 years 3 compared with MMF in use for 8 years in our patient. As in our case, both patients later developed diffuse large B-cell lymphoma of the CNS in which tumour cells showed a positive signal for EBER by ISH. PCNSL have also been reported in patients suffering from other autoimmune conditions including myasthenia gravis, CNS vasculitis, relapsing polychondritis and dermatomyositis, treated with MMF 2 g daily for a variable period of 8-46 months. 4 All of these patients responded to withdrawal of MMF and treatment by rituximab but spontaneous resolution of PCNSL upon discontinuation of MMF and concomitant methotrexate has also been described for a patient with dermatomyositis.
While these case reports suggested a possible association of PCNSL with MMF, SLE patients may be predisposed to the development of lymphoma regardless of immunosuppressant use. A meta-analysis involving over 8700 SLE patients from six cohorts found that NHL was more common in SLE patients with a standardized incidence rate ranging from 5.2 to 44.4. 5 A proportion of these patients had not been treated by immunosuppressive medications 6 implying that development of lymphoma in some patients may not be related to the use of immunosuppressants. Furthermore, the link between MMF and PCNSL and other lymphoproliferative disorders has been reflected in recent decades when MMF has been more widely used and replaced azathioprine in the therapeutic regimen for organ transplant recipients. PCNSL was not uncommonly reported in patients with MMF treated renal transplant recipients with the development of these lesions at a median of 14 months after switching from azathioprine to MMF. 7 Thus, the development of PCNSL in SLE patients may occur as a result of impaired immune surveillance and compromised T-cell activity resulting from the immunosuppressant leading to persistence of EBV, an important aetiological agent for B-cell malignancy, dysregulated apoptosis related to over-expression of oncogenes such as Bcl-2 and malignant transformation from hyperactive B-and T-cells from the underlying lupus. Furthermore, low serum complement profile (C3, C4 and CH50) has been described to be associated with lymphoma in patients with primary Sjogren's syndrome, although only low C4 levels were found to be an independent significant variable in multivariate analysis. 8 Our patient who developed PCNSL after treatment with MMF for almost 8 years provides a third case of possible MMF-associated PCNSL in SLE patients. While our patient was also put on lowdose azathioprine for 6 years, we cannot delineate the risk posed by specific immunosuppressive agents when these were used in combination. Indeed, the Collaborative Transplant Study database showed that azathioprine in combination with corticosteroids predisposed to development of post-transplant lymphoproliferative disease with a relative risk of 12.7 among 6283 cadaveric kidney recipients. 9 However, the association of azathioprine with EBV-related lymphoma in SLE patients is rare. 10 With the more frequent use of MMF clinically in lupus nephritis owing to its efficacy to sideeffect profile compared with cyclophosphamide, and its growing use in non-renal manifestations of SLE, the link between MMF use and the development of lymphoproliferative disorders has yet to be elucidated from surveillance in a large scale. The approach in the management of this condition would include withdrawal of MMF with close monitoring of the lupus disease and judicious use of immunosuppressive agents if necessary.
